Efficacy of Hydroxychloroquine for Post-exposure Prophylaxis (PEP) to Prevent Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection Among Adults Exposed to Coronavirus Disease (COVID-19): a Blinded Randomized Study
Brief description of study
The purpose of this study is to understand if taking a malaria, autoimmunity, and arthritis medication called hydroxychloroquine can reduce the risk of becoming infected with the virus that causes COVID-19 or develop symptoms of COVID-19 after having contact with an infected person. Taking a medication to prevent becoming sick after exposure to an infected person is called “post-exposure prophylaxis” or “PEP.” The current standard of care is no treatment for people who had contact with a known or suspected case of COVID-19. Participants will be assigned by chance (chance is like flipping a coin) to either take hydroxychloroquine PEP or vitamin C for a total of 14 days of treatment which appears to be the approximate incubation period of SARS-CoV-2 infection.
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.
